Heron Therapeutics (HRTX) Downgraded to Hold at Zacks Investment Research
Heron Therapeutics (NASDAQ:HRTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
HRTX has been the topic of several other research reports. Noble Financial reiterated a “buy” rating and set a $24.00 price target on shares of Heron Therapeutics in a research report on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Monday, September 25th. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Cowen reiterated a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Heron Therapeutics currently has an average rating of “Buy” and a consensus target price of $28.82.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. equities research analysts expect that Heron Therapeutics will post -3.39 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in Heron Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 2,383 shares in the last quarter. Quantbot Technologies LP boosted its stake in Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares in the last quarter. Trexquant Investment LP bought a new stake in Heron Therapeutics during the third quarter worth about $206,000. Jane Street Group LLC bought a new stake in Heron Therapeutics during the third quarter worth about $223,000. Finally, HighTower Advisors LLC boosted its stake in Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares in the last quarter. Institutional investors own 98.78% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Heron Therapeutics (HRTX) Downgraded to Hold at Zacks Investment Research” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/heron-therapeutics-hrtx-downgraded-to-hold-at-zacks-investment-research/1804307.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.